Improving AAV vectors via chemical engineering using the AAV-Ligand conjugation platform (ALIGATER™)

被引：0
|
作者：
Jordi, E. [1 ]
Savy, A. [1 ]
Kunalingam, L. [1 ]
Compere, D. [1 ]
Kara-Ali, K. [1 ]
Vidal, P. [1 ]
Brument, N. [1 ]
Mitchell, C. [1 ]
Lefevre, G. M. [1 ]
Francon, P. [1 ]
机构：
[1] Coave Therapeut, Paris, France
来源：
HUMAN GENE THERAPY | 2024年 / 35卷 / 3-4期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P200
引用
收藏
页码：A111 / A112
页数：2
相关论文
共 12 条
  • [1] coAAV Vectors from the AAV-Ligand Conjugate (ALIGATERT) Platform Outperform AAV9 to Address Neurological Disorders via CSF Delivery
    Gougerot, Alexianne
    Savy, Adrien
    Thomasson, Nitza
    Kara-Ali, Kamelia
    Kunalingam, Lavaniya
    Juricek, Ludmila
    Vidal, Patrice
    Lefevre, Gaelle M.
    MOLECULAR THERAPY, 2023, 31 (04) : 526 - 526
  • [2] "Sortagged" AAV: A Novel Chemo-Enzymatic Approach for Site-Specific Ligand Conjugation on AAV Vectors
    Schiavo, Irene
    Groppa, Elena
    Hainberger, Daniela
    Reis, Fernanda De Castro
    Heppenstall, Paul
    MOLECULAR THERAPY, 2024, 32 (04) : 472 - 472
  • [3] Improving the efficiency of AAV gene delivery vectors via capsid design and bioprocess engineering
    Hall, L.
    Massaro, G.
    Rahim, A.
    Majumder, P.
    Rafiq, Q.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A40 - A40
  • [4] IMPROVING THE EFFICIENCY OF AAV GENE DELIVERY VECTORS VIA CAPSID DESIGN AND BIOPROCESS ENGINEERING
    Hall, L.
    Rafiq, Q. A.
    CYTOTHERAPY, 2024, 26 (06) : S210 - S210
  • [5] Generation of novel AAV serotype with enhanced infectivity, specificity, and lower toxicity via π-Icosa™ AAV Capsid engineering platform
    Bu, Y.
    Zhong, Y.
    Dai, Z.
    Zhang, Y.
    Fan, Y.
    Pan, Y.
    Chen, H.
    Liu, L.
    Song, I.
    He, L.
    Li, P.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A98 - A98
  • [6] Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors
    Kay, Christine N.
    Ryals, Renee C.
    Aslanidi, George V.
    Min, Seok Hong
    Ruan, Qing
    Sun, Jingfen
    Dyka, Frank M.
    Kasuga, Daniel
    Ayala, Andrea E.
    Van Vliet, Kim
    Agbandje-McKenna, Mavis
    Hauswirth, William W.
    Boye, Sanford L.
    Boye, Shannon E.
    PLOS ONE, 2013, 8 (04):
  • [7] Engineering and Evolution of Synthetic Adeno-Associated Virus (AAV) Gene Therapy Vectors via DNA Family Shuffling
    Kienle, Eike
    Sens, Elena
    Boerner, Kathleen
    Niopek, Dominik
    Wiedtke, Ellen
    Grosse, Stefanie
    Grimm, Dirk
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2012, (62):
  • [8] Improving cell-specific recombination using AAV vectors in the murine CNS by capsid and expression cassette optimization
    Kawabata, Hayato
    Konno, Ayumu
    Matsuzaki, Yasunori
    Sato, Yumika
    Kawachi, Mika
    Aoki, Ryo
    Tsutsumi, Saki
    Togai, Shota
    Kobayashi, Ryosuke
    Horii, Takuro
    Hatada, Izuho
    Hirai, Hirokazu
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32 (01)
  • [9] Engineering complex genotypes in primary haematopoietic cells using Cas9/sgRNA and AAV donor vectors
    Bak, R. O.
    Dever, D. P.
    Reinisch, A.
    Cruz, D.
    Majeti, R.
    Porteus, M. H.
    HUMAN GENE THERAPY, 2017, 28 (12) : A17 - A17
  • [10] AAV vectors produced by a GMP-compliant and scalable production platform mediate a CNS delivery platform using MRI-guided convection enhanced diffusion in NHP
    Blits, B.
    Kells, A.
    Bankiewicz, K.
    Petry, H.
    HUMAN GENE THERAPY, 2013, 24 (12) : A48 - A48
12